A glaring omission in this interview--Dr. Zivadinov does not mention that phase 2 was a failure. It did not reach its endpoint of >75% restoration of venous flow. In fact, the people treated and the people in the sham arm had the same, sub-par venous return of 50%. In phase 1, treated patients had >75% restored venous flow, and showed better CSF movement a year later. How can he cite anything regarding outcomes in phase 2, if this trial did not meet its endpoint?


Results of the PREMiSe Study on CCSVI in MS: An Interview With Robert Zivadinov, MD, PhD |...
www.vasculardiseasemanagement.com
The Prospective Randomized Endovascular Therapy in MS (PREMiSe) trial studied balloon angioplasty for the treatment of multiple sclerosis. Vascular Disease Management spoke about the results with Robert Zivadinov, MD, PhD, one of the lead investigators.